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Abstract
Highly aerobic organs like the kidney are innately susceptible to ischemia-reperfusion (I/R) injury, which
can originate from sources including myocardial infarction, renal trauma, and transplant. Therapy is mainly
supportive and depends on the cause(s) of damage. In the absence of hypervolemia, intravenous fluid
delivery is frequently the first course of treatment but does not reverse established AKI. Evidence suggests
that disrupting leukocyte adhesion may prevent the impairment of renal microvascular perfusion and the
heightened inflammatory response that exacerbate ischemic renal injury. We investigated the therapeutic
potential of hydrodynamic isotonic fluid delivery (HIFD) to the left renal vein 24 hours after inducing
moderate-to-severe unilateral IRI in rats. HIFD significantly increased hydrostatic pressure within the renal
vein. When conducted after established AKI, 24 hours after I/R injury, HIFD produced substantial and
statistically significant decreases in serum creatinine levels compared with levels in animals given an
equivalent volume of saline via peripheral infusion (P<0.05). Intravital confocal microscopy performed
immediately after HIFD showed improved microvascular perfusion. Notably, HIFD also resulted in
immediate enhancement of parenchymal labeling with the fluorescent dye Hoechst 33342. HIFD also
associated with a significant reduction in the accumulation of renal leukocytes, including proinflammatory
T cells. Additionally, HIFD significantly reduced peritubular capillary erythrocyte congestion and
improved histologic scores of tubular injury 4 days after IRI. Taken together, these results indicate that
HIFD performed after establishment of AKI rapidly restores microvascular perfusion and small molecule
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accessibility, with improvement in overall renal function.
Keywords: acute renal failure, retrograde saline delivery, peritubular capillaries
Ischemia-reperfusion (I/R) injury to the kidney has the potential to result in significant damage and loss of
renal function. The loss of GFR after I/R injury is due in part to multiple factors, including damage to renal
tubules, which have been proposed to increase intraluminal pressures and negatively influence net
filtration.  I/R injury can compromise vascular function leading to reduced renal blood flow and alterations
in microvascular perfusion patterns.  The resultant effects of impaired vascular function in the setting of
I/R are at least two-fold. First, increased renal vasoconstriction reduces net glomerular hydrostatic pressure
to reduce GFR. Second, impaired perfusion distribution through the postglomerular vasculature may
exacerbate the degree of hypoxia thus sustaining or exacerbating the degree of tubular damage.
To date, treatment of patients with AKI is limited primarily to supportive care, by maintaining extracellular
fluid volume and electrolyte balance over a critical period during which endogenous processes may
mediate injury resolution and repair of damaged tissue.  However, there has been no significant advance in
therapies to treat patients with established AKI, either to improve function or facilitate repair processes.
Given the importance of renal perfusion in the pathophysiology of I/R-induced AKI, there has been
significant attention on potential treatments designed to improve renal blood flow to mitigate AKI.
Although vasodilators have shown efficacy in AKI prevention in animal models,  these therapies have not
translated to effective clinical therapy as noted by the failure of renal dose dopamine to improve AKI.
In recent years, the concept of the extension phase of AKI has been articulated, in which postischemic
activation of an inflammatory process results in vascular congestion.  Significant evidence exists that I/R-
induced expression of surface adhesion molecules, such as ICAM-1, on the endothelium promotes
leukocyte adhesion. Adherent leukocytes contribute to renal injury by impairing perfusion and by
production of cytokines, which enhances inflammatory responses, further promoting tissue damage. The
no-reflow phenomenon contributes to AKI in animal models and impaired microvascular perfusion
associated with red cell congestion can be readily imaged in vivo using light microscopy.  Yamamoto et
al. demonstrated that endothelial dysfunction was a primary contributor to microvascular flow distortions
after I/R injury.  Wu et al. and more recently Nakano et al. used intravital light microscopy to demonstrate
reduced capillary blood flow and tubule fluid flow in an LPS injury model.
Vascular congestion distal to the efferent arteriole vasculature may be a primary factor in reducing
perfusion and driving the extension phase. Leukocyte adhesion is prominent in the postischemic kidney
primarily with low hydrostatic pressure. Therefore, it is reasonable to search for treatments geared toward
reducing vascular congestion in capillaries and venules. Because increasing hydrostatic pressure perturbs
leukocyte adhesion, an elevation of pressure in regions may clear existing congestion and help to re-
establish effective perfusion. Renal vein hydrodynamic isotonic fluid delivery (HIFD) effectively
administers macromolecules to the kidney for use in exogenous gene expression.  This process may be
dependent on an increase in intravascular pressure focused transiently at the level of the peritubular
capillary network.  Because of this, we hypothesized that renal vein HIFD may effectively reverse
established I/R-induced AKI by re-establishing renal perfusion. We evaluated this hypothesis by
investigating HIFD treatment after establishment of AKI in rats.
Results
Correlative Light and Electron Microscopy of I/R-Injured Kidneys
In prior reports, intravital light microscopy studies found microvascular changes in white cell adhesion in
1
–1 4
1
5
6
7
3
, ,3 8 9
4
,10 11
12
12
Hydrodynamic Isotonic Fluid Delivery Ameliorates Moderate-to-Severe ... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491274/?report=printable
2 of 23 5/21/2019, 1:52 PM
the setting of I/R injury.  In addition to changes in white cell adhesion to the endothelium, red cell stacks
identified as large negatively stained areas are readily observed in a 24 hours postischemic kidney (Figure 1
, arrows). The extended size and relative lack of movement of these structures suggested that rouleaux were
causing microvascular occlusion in the postischemic kidneys. To confirm, we performed a correlative
experiment in which a region of interest (ROI) identified by intravital light microscopy was sampled by
biopsy, followed by rapid freeze fixation to evaluate ultrastructural changes observed at light microscopy
resolution. Figure 1A illustrates the presence of aggregate of red blood cells occluding the capillary lumen
by light microscopy, whereas Figure 1B illustrates the same region at ultrastructural resolution. Figure 1C
illustrates capillary cross section with a nonoccluding red cell as commonly observed in control,
nonischemic kidneys. These observations are consistent with long-standing observations of vascular
congestion observed macroscopically in postischemic kidneys.
Hydrodynamic Delivery of Saline via the Renal Vein Is Sufficient to Ameliorate the Course
of AKI
HIFD effectively delivers macromolecules to cells in kidneys.  The combination of a pressurized transient
fluid injection results in permissive fluid passage through fenestrated endothelium and may disrupt vascular
congestion directly.
To test the effect of HIFD on the course of AKI, I/R injury was induced by right unilateral nephrectomy
and left renal pedicle cross clamp in rats. At 24 hours post-I/R, plasma creatinine levels were measured and
rats were subjected to either renal HIFD into the left renal vein or a control injection of an equivalent saline
volume into the vena cava. Rats were allowed to recover for an additional 1 or 3 days (i.e., 2 or 4 days post-
I/R). HIFD resulted in a transient increase in renal venous pressure from approximately 6.5 to 66.5±6
mmHg (Figure 2A). HIFD eliminated regions of hypoperfusion readily observable grossly in a
postischemic kidney (Figure 2B, left panel, arrows, compared with the right panel). In both 2- and 4-day
cohorts of vena cava–injected rats, the plasma creatinine values continued to rise between 24 and 48 hours,
whereas rats subjected to renal vein HIFD manifested a significant decline in plasma creatinine (
Figure 2, C and D). Indeed, when combining data from all rats, the change in plasma creatinine between 24
and 48 hours was improved in HIFD-treated rats by 1.65±0.34 mg/dl (Figure 2E). This procedure was also
associated with a significant acceleration in recovery of renal morphology as illustrated by the
improvement in renal tubular damage present at 4 days after I/R in HIFD- versus vena cava–treated rats (
Figure 2, F–H).
Hydrodynamic Delivery of Saline via the Renal Vein Re-Establishes Capillary Perfusion
Post–I/R Injury
Renal histology shown in Figure 2F demonstrated the sustained presence of red blood cells (RBCs) in renal
capillaries in vena cava–injected post-AKI rats (Figure 2F, black arrows), whereas rats showed a significant
reduction in RBCs after HIFD (Figure 2, F–I). Therefore, we hypothesized that HIFD may accelerate
recovery by improving renal perfusion. To investigate further HIFD effects, we performed intravital light
microscopy on kidneys 24 hours after I/R injury immediately before and immediately after HIFD therapy.
In keeping with prior studies, we found areas of hypoperfusion corresponding to regions where red cell
ghosts are seen consistent with rouleaux (Figure 3B, Supplemental Movies 1 and 2). Imaging the same
kidney after HIFD revealed improved capillary bed perfusion with less observable rouleaux (Figure 3C,
Supplemental Movie 1). Analysis of RBC velocity suggested that renal I/R resulted in an approximately
81% reduction in microvascular perfusion relative to sham-operated control rats. RBC velocity, although
still suppressed versus sham, was significantly improved 2.3-fold by HIFD by within 30 minutes of the
procedure (Figure 3D).
In addition to improvements in microvascular perfusion, an unexpected result revealed by these studies
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Efficacy of HIFD in the Absence of Renal Artery Clamping
came from the use of Hoechst 33342, which is routinely included in intravital light microscopy studies to
label nuclei. Hoechst 33342 has a mol wt of 452 g/mol and it efficiently labels cell nuclei because of its cell
permeant properties.  Its size is equivalent to the mol wt of small molecule therapeutic agents. Figure 3B
illustrates that Hoechst 33342 nuclear labeling is weak as compared with sham (Figure 3A), with an
average fluorescent intensity of 20.12±2.8 (Figure 3E). After HIFD, nuclear labeling is stronger (Figure 3C
, arrows) and average fluorescence intensity measurement of nuclei was significantly enhanced (Figure 3E;
73.2±1.1; P<0.05). Notably, Hoechst 33342 was injected via the tail vein when the experimental
preparation was started. No additional Hoechst 33342 was given during the study, so the change in nuclear
staining likely reflects improved microvascular perfusion allowing label to enter cells. To eliminate the
possibility that HIFD treatment disrupts vascular permeability, we modified our experimental procedure
where 150 kD tetramethyl rhodamine isothiocyanate (TRITC)–conjugated dextran was injected via tail
vein, 20 minutes after HIFD. The animals had a right nephrectomy with contralateral I/R injury 24 hours
before HIFD therapy. Image collection in a single plane over time was performed to assess diffusion of the
high–mol wt fluorescent probe into the interstitial space. Figure 3F shows that there is no change in
vascular permeability between pre– or post–HIFD-treated kidneys. Hoechst 33342 given concomitant with
the high–mol wt dextran, both given by a peripheral intravenous infusion, is now able to label nuclei,
confirming that HIFD improves delivery of Hoechst 33342 to cells by re-establishing capillary perfusion
and not by altering vascular permeability.
Hydrodynamic Delivery of Saline via the Renal Vein Reduces Inflammatory Cell Infiltration
Post–I/R Injury
To determine if HIFD reduced infiltration of leukocytes, we measured mononuclear cell populations 2 days
after I/R. We observed that I/R injury increased the total number of mononuclear cells, infiltrating CD4+ or
CD8+ lymphocytes, CD4+17+, CD8+IL-17+ cells, B cells, and dendritic cells/macrophages (DC/Macs)
compared with sham (P<0.05). Interestingly, total mononuclear cell number, CD4+ or CD8+ lymphocytes,
CD4+17+, CD8+IL-17+ cells, B cells, and DC/Macs were all significantly reduced after HIFD (P<0.05).
Neither AKI nor HIFD had an effect on Th1 or Th2 polarization (Figure 4, Table 1).
In addition, T regulatory cells are associated with modulating T cell activity after renal injury.
Interestingly, within 2 days of I/R injury, the percentage of CD4+Foxp3+ cells was significantly greater in
HIFD-treated rats compared with vena cava–treated rats (Table 1).
To test whether HIFD may translate to
clinical settings using intravascular approaches, we repeated the HIFD studies without clamping the renal
artery during the perfusion. Although a kidney hydrodynamic pulse is feasible with a renal vein catheter,
simultaneous renal artery and venous cannulation would probably exacerbate kidney ischemia and is
technically difficult. Therefore, we conducted an additional study to test the efficacy of HIFD in the
absence of renal artery clamping. Similar to observations in the presence of renal pedicle clamping, HIFD
without renal artery clamping also resulted in significant reduction in serum creatinine (Figure 5A).
Comparing serum creatinine at day 2 to day 1, the change in serum creatinine for HIFD-treated animals
was −0.33. In contrast, the change in serum creatinine for animals given saline via the vena cava was 1.51.
There are significant reductions in infiltrating inflammatory cells, CD4, and CD8 cells in HIFD animals (
Figure 5, B and C). IL17-positive cells were also diminished in HIFD-treated animals (Figure 5D) and
subtype studies showed that CD4+/IL17+ and CD8+/IL17+ cells both decreased in HIFD-treated animals
as well (Figure 5, E and F). Finally, we also found that HIFD performed with the renal vein occluded
restored capillary blood flow to the same degree as HIFD performed with artery and vein occlusion (
Figure 5G).
Discussion
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AKI is a syndrome characterized by the rapid loss of the kidney’s excretory function leading to
unacceptably high morbidity and mortality.  The rapid decline in renal function is associated with
decreased renal perfusion, tubular necrosis, and damage to the glomeruli, interstitium, and vasculature.
Although the tubules are a major target of injury as indicated by severe morphologic damage, endothelial
dysfunction contributing to vascular congestion and inflammation represent principal components of the
extension phase of injury. This extension phase, described by Sutton and Molitoris, recognizes that
impaired perfusion post-AKI may exacerbate hypoxia and result in greater tubular damage than would be
seen if perfusion remained intact.  It has been suggested that targeting the extension phase may represent
a significant advance in the treatment of AKI,  however, to date there have been no Food and Drug
Administration–approved available treatments which have shown significant efficacy in targeting these
activities. The components of the extension phase are more pronounced in the outer medullary region of the
kidney, where reduced blood flow, stasis, and accumulation of red and white cells is most prominent.
It is during this phase that renal vascular endothelial cell damage likely plays a key role in the
inflammatory response observed with ischemic AKI.  Inflammatory cell infiltration is a prominent early
feature in the outer medullary vasa recta capillaries after injury. Animal models of AKI show that ischemic
injury is accompanied by the rapid influx of leukocytes, lymphocytes, dendritic cells, and macrophages into
the interstitium.  Particularly, there is growing evidence supporting an important role of T cells in
AKI.  How T cells promote injury is still under investigation, however, it is possible that this activity is
secondary to alterations in the endothelium. Endothelial cells have a significant increase in surface
expression of leukocyte adhesion molecules such as ICAM-1, along with P- and E-selectin, in response to
injury.  Treatments geared toward reducing endothelial/leukocyte interactions by targeting these
endothelial adhesion molecules preserve blood flow and protect against renal damage in ischemic AKI in
preclinical models of renal I/R.  Interestingly, whereas studies in transplant suggest that anti–ICAM-1
may prevent AKI, other studies using ICAM-1 demonstrate no effect after AKI was established in settings
such as in toxic AKI.
Vascular congestion is an important feature contributing to the severity of AKI.  Ischemia causes
the upregulation of genes such as ICAM-1 and vascular cell adhesion protein 1 and the downregulation of
the endothelial glycoprotein thrombomodulin.  A combination of activated leukocytes binding to
adhesion molecules, endothelial damage, and platelet aggregation leads to microvascular congestion and
reduced perfusion.  After the reduction in renal perfusion, epithelial cells are unable to maintain
intracellular ATP leading to cell injury, potentially leading to apoptosis or necrosis.  That RBC congestion
plays a critical role in the genesis of tubular injury and loss of renal function is supported by studies from
Hellberg and Olof et al. demonstrating that a reduction in the hematocrit reduced post-ischemic erythrocyte
congestion, and improved GFR and renal morphology.
Improvement of renal vascular perfusion in the setting of AKI is a potential therapy in the treatment of
AKI. However, although vasodilator therapies have shown promise in preventing renal injury before
ischemia, their ability to improve renal function after established AKI has been limited.  Clinically,
renal-dose dopamine has not translated to improvement in patients with AKI.  However, as
peritubular capillaries are among the first structures affected during an ischemic insult, it is likely that their
impaired blood flow rates and lower hydrostatic pressure combine to promote leukocyte adherence and
congestion.  Because vascular congestion occurs distal to the efferent arteriole and is a significant factor in
reducing perfusion and driving the extension phase, it is reasonable that timely vascular therapies
influencing preglomerular vascular tone lack efficacy in treating established AKI. We hypothesized that an
increase in hydrostatic pressure may disrupt vascular congestion, leading to the resolution of established
AKI. High-pressure (66±5.74 mmHg) HIFD into the renal vein resulted in a near immediate reduction in
serum creatinine (Figures 2A and 5A), an alleviation of microvascular rouleaux (Figures 2F and 3, B and C
), and an improvement of RBC velocity (Figures 3D and 5G). HIFD therapy also improved tissue injury
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scores 4 days post-I/R (Figure 2, F–H). A striking result of our experiments is that a single intervention
performed 24 hours after injury is capable of leading to sustained improvement in renal function and tissue
morphology. This strongly underscores the benefit of resolving microvascular congestion post-AKI.
Whether HIFD is translatable to the clinical setting is unclear. This study used an invasive approach where
isotonic saline injected retrograde into the renal vein improves renal function after I/R injury. Although this
open, invasive procedure is not practicable to treat established human AKI, other intravascular approaches
using endovascular catheters can effectively deliver solutions via retrograde delivery in large animal
models and humans.
The proposed lack of no-reflow in large animal models as well as humans is often a point of contention
with the use of various animal models in experimental AKI.  However, several of these studies
described a lack of the no-reflow phenomenon where renal blood flow returned to baseline levels very early
(e.g., 2 minutes) after reperfusion.  This is consistent with rodent data, where blood flow returns to
baseline levels early after reperfusion, but declines over time.  Vascular congestion and peritubular
capillary derangement manifesting hours and days after reperfusion are demonstrably important in the
pathogenesis of AKI in large animal models and humans.  For example, Mandal et al.
demonstrated that I/R caused significant rouleaux formation in dogs, which was alleviated by
splenectomy.  Further, Solez et al. demonstrated that 63 of 66 cadaver kidneys from patients with AKI for
>24 hours’ duration had significant intravascular leukocyte accumulation.  Alleviation of vascular
congestion and improvement of renal microvascular blood flow by HIFD demonstrates a potential
mechanism that supports the concept of establishing full tissue level perfusion in patients with established
AKI.
To determine if HIFD influenced leukocyte infiltration, we evaluated immune cell populations after
surgery. In addition to improved perfusion, we hypothesized that the HIFD procedure reduces the
inflammatory state post–I/R injury. That both innate and adaptive immune systems play a role in I/R injury
is well established.  After I/R, the injured renal parenchymal cells facilitate the trafficking of, for instance,
innate lymphoid cells like leukocytes, B cells, dendritic cells, and macrophages into the kidney.  The
balance between pro- and anti-inflammatory mediators significantly affects the extent of injury and
reparative mechanisms.  Inflammation also causes anticoagulant production to be significantly decreased
after ischemic AKI.  Several reports have indicated that T cells contribute to renal injury after
I/R.  Recently, Chan et al. and our group suggested that IL-17 cytokine plays an important role in
AKI.  Here we show that at 24 hours post-AKI, renal vein HIFD significantly decreases the number of
infiltrating T cells (CD4+, CD8+), IL-17 cells (Figures 4 and 5), B cells (Table 1), and DC/Macs (Table 1),
indicating that retrograde HFID is a novel and effective treatment to reduce inflammation after injury. It is
likely that these inflammatory cells or proinflammatory cytokines exit from kidney parenchyma leading to
decreased cell infiltration. Additionally, HIFD increased the percentage of T regulatory cells, suggesting a
shift from pro- to anti-inflammatory phenotype. Taken together, these data suggest that HIFD may improve
renal function by improving vascular perfusion as well as decreasing the injurious effects of infiltrating
leukocytes after injury is established.
In summary, data presented here demonstrate for the first time a novel approach to treating established
AKI. In addition to treating established AKI, HIFD may have other additional advantages. Several
pharmacologic agents that have been shown to prevent AKI have been employed or are in the pipeline for
the treatment of established AKI, such as antiapoptosis/necrosis agents,  free radical scavengers,
antisepsis agents,  anti-inflammatory drugs,  loop diuretics,  and vasodilators.  In a recent
review, Okusa has summarized the numerous clinical trial failures, where pharmacologic interventions are
attempted after AKI is established.  Our data suggest that a common cause of failure is a defect in target
cell delivery of pharmacologic agents. The HIFD approach may prove effective where other attempts have
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failed in AKI therapy and prevention of CKD. Beyond isotonic saline, pharmacologic agents or small
molecules (Figure 3C) that fail to reach kidneys effectively when given systemically may better treat AKI
via HIFD.
Concise Methods
Animal Care and Use
Male Sprague Dawley rats (Harlan Laboratories, Indianapolis, IN), with weights ranging from 225 to 300
g, were used for these studies. Rats had free access to standard rat chow and water throughout our studies.
Experiments were conducted in accordance with the National Institutes of Health (NIH) Guidelines and
were approved by the Indiana University School of Medicine Institutional Animal Care and Use
Committee.
Rat Kidney I/R Injury Model
AKI was induced by procedures similar to those described previously  with modifications described
subsequently. Rats were anesthetized with intraperitoneal injections of ketamine (100 mg/kg) with xylazine
(5 mg/kg) and then placed on a heating pad to maintain physiologic temperature. For studies in which
confocal images were conducted, acepromazine (1 mg/kg) was also included in the anesthesia. An
abdominal midline incision was made and the right renal artery, vein, and ureter were ligated using 4–0
silk. The right kidney was bluntly dissected free and removed. Unilateral I/R was induced by occluding the
left renal pedicle with microaneurism clamps (Fine Science Tools, Foster City, CA) for 40 minutes. At the
end of the ischemic period, the clamp was removed to reinitiate renal blood flow. Upon visual confirmation
of renal reperfusion, animals were allowed to fully recover from anesthesia.
HIFD
HIFD was conducted similarly to the method which facilitates plasmid delivery to rat kidneys  with
modifications described subsequently. Twenty-four hours after I/R injury, rats were anesthetized under
isoflurane and the left renal pedicle was exposed. The renal vein was bluntly dissected and then elevated
with either 3–0 or 4–0 silk suture thread. The renal pedicle was occluded with a micro serrafine clamp and
0.5 ml of saline was immediately injected retrograde into the vein (i.e., toward the kidney) over a period of
approximately 4 seconds, using a 30 gauge stainless steel needle attached to a 1 ml syringe, at the site
between the suture and the kidney. Under these conditions, the kidney transiently swells due to fluid
injection. The needle was removed, and pressure was applied to the injection site using a cotton swab to
induce hemostasis. The vascular clamp was removed to restore renal blood flow, and the total occlusion
period was predetermined to equal 3 minutes. After this, the midline incision was closed and the animal
was allowed to fully recover. In additional studies performed to examine the effect of renal vein occlusion
during HIFD procedures, only the renal vein was occluded without clamping the renal artery (HIFDrv).
Otherwise, HIFD was performed as described above.
In some experiments, renal venous pressure was measured simultaneous to HIFD. In these studies, a second
30 g needle shaft was removed from its hub and attached in parallel with the needle used for delivery of
saline using Vetbond (3M), such that the tips of both needle shafts were closely opposed to each other, and
both tips could be introduced and removed from the renal vein with minimal damage. The distal end of the
needle was attached to a PE-10 polyethylene catheter tube, which was filled with heparinized saline, and
connected to a fluid pressure transducer (World Precision Instruments, Sarasota, FL). Signals from the
transducer were amplified with a Transbridge amplifier (World Precision Instruments) and acquired in real-
time using data-acquisition software (Biopac Systems, Goleta, CA).
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Materials
All fluorescent-tagged chemicals, with the exception of fluorescent-tagged dextran, were purchased from
Molecular Probes–Thermo Scientific (Waltham, MA). Fluorescence-conjugated 150 kD dextran was
purchased from TdB Consultancy (Upsalla, SW). Sterile saline was purchased from Baxter–Travenol
(Deerfield, IL). Diaminobenzidine and lead acetate were purchased from Electron Microscopy Sciences
(Hatfield, PA).
Serum Creatinine Measurements
At the indicated times, blood was obtained from rats under light isoflurane anesthesia via tail vein
incisions. Blood was collected in 1 ml Eppendorf, heparin-treated tubes, centrifuged at 3000 g for 10
minutes, and the plasma stored at 4°C. Serum creatinine was measured using a Point Scientific QT 180
Analyzer and creatinine reagent kit (Point Scientific, Inc., Canton, MI) according to the manufacturer’s
specifications.
Florescence Cell and Tissue Markers
The following fluorescent probes were used in our intravital two-photon fluorescent imaging studies: 150
kD TRITC dextran (TdB Consultancy) and Hoechst 33342 (ThermoFisher Scientific, Waltham, MA). Each
dextran solution was prepared by diluting 500 μl of a 20 mg/ml stock solution in 1 ml of saline. We also
used 30–50 μl of Hoechst 33342 (Invitrogen, Carlsbad, CA) that was diluted in 0.5 ml saline.
Correlative Light and Electron Microscopy
Twenty-four hours after I/R injury, the animals were anesthetized with isoflurane, infusion catheters were
placed in the carotid artery, and the rats were injected with Hoechst 33342 and 150 kD fluorescein-
conjugated dextran (TdB Consultancy), as previously described.  Imaging was performed with a BioRad
MRC 1024 two-photon confocal microscope attached to an inverted Nikon microscope.  When an ROI
was identified, a biopsy sample was taken using the microbiopsy system (Leica Microsystems, Vienna,
Austria). For these specimens, the sample holder was not dipped in hexadecane. The samples were quickly
loaded into a slotted specimen holder using the transfer station. Any space left in the specimen holder was
filled with hexadecane and frozen.
Biopsy samples of kidney were prepared for electron microscopy by freeze substitution and low-
temperature embedding using a Leica EMPACT (Leica Microsystems, Vienna, Austria) High Pressure
Freezer. Samples were frozen at 2100 bar with an average cooling rate of −13,000°Ks . Once the samples
were frozen they were stored in liquid nitrogen until they were ready for freeze substitution.
Freeze Substitution and Embedding
All samples were freeze-substituted using a Leica Automatic Freeze Substitution Unit (Leica
Microsystems, Vienna, Austria). Samples were freeze-substituted in 0.01% osmium tetroxide, 0.1%
gallium arsenide, 0.25% uranyl acetate in acetone, and embedded in LR Gold (Electron Microscopy
Services, Hatfield, PA). The freeze substitution schedule was as follows; −90°C for 3 days, warmed to
−25°C at 5°C/h, then at −25°C for 6 hours. Some of the samples were warmed to 0°C over a 2.5-hour
period, rinsed with 100% acetone, warmed to room temperature, and infiltrated in 1:2 resin/acetone for 2
hours followed by 2:1 resin/acetone overnight. Samples were embedded and then polymerized at −20°C.
Sections were cut with a Leica Ultracut UCT Ultramicrotome (Leica Microsystems, Vienna, Austria).
Sections were imaged with an FEI electron microscope equipped with an AMT charged-coupled device
camera.
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Intravital Light Microscopy Assessment of Capillary Blood Flow, Vascular Permeability,
and Hoechst 33342 Labeling
Twenty-four hours after renal I/R injury, isoflurane-anesthetized rats were prepared for intravital light
microscopy as described above. A line scan was generated from the center of the vessel of interest
continuously at a rate of 2 milliseconds per line for 1 second (1000 total lines). The scan measures flowing
red blood cells, which do not take up dye and are therefore black. To analyze the scan, all channels of the
line scan are merged into a single channel. This results in a vertical axis denoting time and a horizontal axis
denoting the length of the scan, or distance. The velocity of the blood cells was determined using the dark
lines which depict the movement of the blood cell along the scan over time. The flow velocity was
determined by measuring the slope as described by Dunn et al.  and Lin et al.
A complementary approach was taken to measure vascular permeability after HIFD. Twenty-four hours
after performing postnephrectomy, contralateral I/R injury, HIFD was performed on the remnant kidney.
Twenty minutes after HIFD, 150 kD TRITC-conjugated dextran and Hoechst 33342 were injected via the
tail vein. Intravital imaging was performed on the kidney at a rate of 2 milliseconds per line for a total of 5
minutes. Vascular permeability was determined by measuring the change in red channel fluorescence along
a line perpendicular to a capillary wall. Sequential changes in fluorescent intensity over time were used to
determine the rate of high–mol wt dextran entry into the interstitial compartment. Ten fields were studied
for each animal and statistical significance was determined at a P value <0.05 using paired t test.
To evaluate changes in Hoechst 33342 signal, 512 × 512 image scans were collected with simultaneous
acquisition of 420 and 514 nm wavelengths at 1 scan/s using 800 nm excitation light in two-photon mode.
Thirty scans were acquired from each animal with random field selection. Images were acquired 24 hours
post–I/R injury and 20 minutes after HIFD in post–I/R injury rats. Images were collected from sham-
operated rats. Image intensity values were obtained by defining a circular ROI. Average intensity values
were obtained by placing the ROI over nuclei in all cells in a field using ImageJ (NIH).  Statistical
significance was determined using paired t test.
Evaluation of Renal Tubular Damage and RBC Congestion
Renal tubular damage was evaluated from formalin-fixed paraffin-embedded samples stained using
hematoxylin and eosin. Six random images (three cortex, three outer medulla) were obtained using a Leica
DMLB microscope (Scientific Instruments, Columbus, OH) using a 20× objective. For each kidney, an
average of 60 tubules were scored from images by an observer who was blinded to the treatments using a
modified one to four scoring system described previously.  Data presented are on the basis of the average
score per tubule corresponding to each animal.
RBC congestion was analyzed using ImageJ software, whereby regions of interest were identified visually
and used to calculate percentage surface area.
Assessment of Renal Infiltrating Cells
Harvested kidneys were minced and digested with liberase (2 µg/ml; Roche, Basel, Switzerland) for 15
minutes at 37°C using Gentle MACs (Miltenyi, San Diego, CA). Digested tissue was filtered through a 100
μm filter mesh and washed with medium. Mononuclear cells were separated by Percoll (Sigma-Aldrich, St.
Louis, MO) and counted by hemocytometer. To evaluate T lymphocytes, the cells were stained with
antibodies against rat CD4 (PE-Cy7), CD8a (Alexa 647), and CD161 (PE-Cy7). To evaluate the T helper
subtype, the cells were permeabilized and stained with antibodies against cytokines such as IFN-γ (FITC;
Th1), IL-4 (PE; Th2), and IL-17 (FITC; Th17). To evaluate regulatory T cells, mononuclear cells were
stained with either CD4 or CD4 along with Foxp3 (PE). To evaluate B cells and DC/Mac mononuclear
cells were labeled with antibodies against RTIB (FITC) and Cd11b/c (PE), respectively. Fluorescence was
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measured using flow cytometry (FACSCalibur; BD Biosciences, San Jose, CA) and dot plots were
analyzed using Flowjo software (Tree Star, Ashland, OR). Lymphocyte gating strategy was identical to that
shown previously.  The data are expressed as a total number of the specific cell population per gram of
kidney.
Statistical Analyses
Statistical analysis of changes in serum creatinine was performed by paired t test with significance
determined at a P value <0.05. Statistical analysis for RBC flow velocity and Hoechst intensity before and
after HIFD was performed by paired t test with significance determined at a P value <0.05.
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Figure 1.
Rouleaux formation within the renal microvasculature after renal I/R. (A) Multiphoton imaging of renal microcirculation
was conducted using 150 kD FITC dextran 24 hours after renal I/R injury; vascular congestion and stacked red blood cells
are evident in the cortical microvasculature after I/R (white arrows). (B) Electron microscopy of the highlighted region in
(A) after correlative tissue sampling and subsequent cryofixation after high-pressure freezing demonstrating red blood cell
congestion in peritubular capillaries (arrows). (C) Capillary cross section in a control, nonischemic kidney. Sample was
cryofixed after high-pressure freezing. Magnifications are listed below electron micrographs. DT, distal tubule; PT,
proximal tubule.
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Figure 2.
Open in a separate window
HIFD improves renal function and structure post-AKI. Rats were subjected to unilateral nephrectomy and unilateral I/R
and allowed to recover for 24 hours before HIFD or vena cava saline infusion. (A) Representative tracing of renal venous
pressure during HIFD, (B) (left panel) gross images of post-AKI kidney before, and (B) (right panel) 3 minutes after HIFD
in the same kidney. Note elimination of striated zones of hypoperfusion post-HIFD (left panel, arrows). (C and D) Serum
creatinine (sCre) versus time after HIFD or vena cava injection 24 hours post-I/R in rats recovering for 2 days (C) or 4
days (D) postsurgery. (E) Change in serum creatinine in the 24-hour period immediately after HIFD in all 2- and 4-day–
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treated rats (A–E); N for each group is shown at each time point; *P<0.05 in HIFD versus vena cava by unpaired t test. (F)
Representative renal histology 4 days post-I/R. Cross sections of hematoxylin and eosin stained cortex and outer medulla
from sham, I/R + vena cava injection, or I/R + HIFD in cortex are shown. Black arrows indicate congested RBCs in
peritubular capillaries. (G and H) Renal injury scores on the basis of renal histology of kidney tissue ([G] cortex; [H] outer
medulla) from (F). (I) Quantification of cortical vascular congestion expressed as percentage of total area from (F). (G–I)
* P<0.05 for sham versus *I/R + vena cava or I/R + HIFD; P<0.05 for I/R + vena cava versus I/R + HIFD by paired t
test. *P<0.05 in HIFD versus vena cava by unpaired t test.
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Figure 3.
HIFD immediately improves vascular congestion in a post-AKI kidney. Live multiphoton imaging of sham kidney (A) or
kidneys 24 hours post I/R, immediately before (B) and 30 minutes post–HIFD injection (C) are shown. (D) A line scan
was generated and is indicative of average RBC velocity in the capillary space pre– and post–HIFD injection. (E) Average
nuclear fluorescent intensity of Hoechst 33342 signal in tubular epithelial cells pre- and post-HIFD; for (D) and (E), data
are mean±SEM of fluorescent intensity (arbitrary units) of 10 ROI of images from three separate experiments for sham or
pre- and post-HIFD. (F) Fluorescent intensity per unit time in sham versus pre– and post–HIFD-treated rats. Fluorescent
intensity (arbitrary units) of the interstitial space fluorescence as a percentage of tubule fluorescence of 10 ROI of images
from three separate experiments. * P<0.05 for sham versus *pre-HIFD or versus post-HIFD using paired t test; P<0.05
for pre-HIFD versus post-HIFD using paired t test.
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Figure 4.
HIFD reduces the number of inflammatory cells 48 hours postsurgery. Kidneys from rats after sham surgery, I/R + vena
cava, or I/R + HIFD 2 days after surgery were used for isolation of monocytes and FACS for the following populations:
(A) total number of infiltrating cells, (B) IL17 CD4  cells, and (C) IL17+CD8+. Data are expressed as mean±SEM
number of cells per gram kidney weight; * P<0.05 for sham versus *I/R + vena cava or I/R + HIFD; P<0.05 for I/R +
vena cava versus I/R + HIFD by paired t test.
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Table 1.
Effect of HIFD on infiltrating inflammatory cells 2 days post–I/R injury
Cell Type Treatment
Sham Vena Cava HIFD
CD4+ 6272±3839 21,101±4198 9987±2964
CD8+ 5097±4506 15,444±2637 8474±1468
B cells 2351±1510 5743±1609 2868±880
DC/Macs 12,695±5433 34,684±7758 21,495±3880
CD4+IL-4+ (Th1) 161±58 280±52.8 200±50
CD4+IFN-γ+ (Th2) 277±82 1301±667 399±113
% CD4+Foxp3+ 0.7±0.01 0.405±0.04 0.72±0.08
% CD8+Foxp3 0.35±0.1 0.15±0.02 0.29±0.06
The table shows different subtypes of infiltrating mononuclear cells in the kidney 48 hours postinjury in sham, I/R +
vena cava, or I/R + HIFD. The data are shown as the number of cells/g of kidney. Data are expressed as mean±SEM.
P<0.05 sham versus I/R + vena cava.
P<0.05 in I/R + vena cava versus I/R + HIFD.
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Figure 5.
HIFD  improves renal function, reduces the number of inflammatory cells, and improves microvascular perfusion. Rats
were subjected to unilateral nephrectomy and unilateral I/R and allowed to recover for 24 hours before HIFD or vena cava
saline infusion. In contrast to initial studies, only the renal vein was occluded before and during HIFD (HIFD ). (A)
Serum creatinine versus time after HIFD  or vena cava injection 24 hours post-I/R in rats recovering for 2 days (n=12 for
rats treated with HIFD with the renal vein occluded versus n=11 for rats given saline via the vena cava; *P value=0.001).
Kidneys from rats after sham surgery, I/R + vena cava, or I/R + HIFD  2 days after surgery were used for isolation of
monocytes and FACS for the following populations: (B) total number CD4+ cells, (C) CD8+  cells, (D) total number of
IL17+ cells, (E) CD4+IL17+ cells, and (F) CD8+IL17+ cells. (G) A line scan captures average RBC velocity in the
capillary space comparing pre– and post–HIFD injection versus pre- and post-HIFD  For FACS analysis, data are
expressed as mean±SEM number of cells per gram kidney weight; * P<0.05 for sham versus *I/R + vena cava or I/R +
HIFD ; P<0.05 for I/R + vena cava versus I/R + HIFD  by paired t test).
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